These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19749489)

  • 21. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dasatinib.
    Kantarjian H; Jabbour E; Grimley J; Kirkpatrick P
    Nat Rev Drug Discov; 2006 Sep; 5(9):717-8. PubMed ID: 17001803
    [No Abstract]   [Full Text] [Related]  

  • 23. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
    Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of Bcr-Abl-positive leukemias with dasatinib.
    Hochhaus A
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1529-36. PubMed ID: 18020922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Goldman JM; Melo JV
    N Engl J Med; 2001 Apr; 344(14):1084-6. PubMed ID: 11287980
    [No Abstract]   [Full Text] [Related]  

  • 26. The FDA approves new leukemia drug; expands use of current drug.
    FDA Consum; 2006; 40(6):5. PubMed ID: 17338066
    [No Abstract]   [Full Text] [Related]  

  • 27. Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion.
    Tachibana T; Numata A; Tanaka M; Motohashi K; Fujisawa S; Fujita H; Sakai R; Tomita N; Maruta A; Ishigatsubo Y; Kanamori H
    Leuk Lymphoma; 2011 Jul; 52(7):1376-9. PubMed ID: 21438838
    [No Abstract]   [Full Text] [Related]  

  • 28. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
    Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
    J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic inhibition of the Bcr-Abl kinase with STI571: a novel, safe, and effective therapy for chronic myeloid leukemia.
    Press RD
    Mol Diagn; 2001 Sep; 6(3):211-3. PubMed ID: 11571715
    [No Abstract]   [Full Text] [Related]  

  • 30. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Narayanan V; Pollyea DA; Gutman JA; Jimeno A
    Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
    Klyuchnikov E; Schafhausen P; Kröger N; Brummendorf TH; Osanmaz O; Asenova S; Zabelina T; Ocheni S; Ayuk F; Zander AR; Bacher U
    Acta Haematol; 2009; 122(1):6-10. PubMed ID: 19602874
    [No Abstract]   [Full Text] [Related]  

  • 32. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Sakamaki H; Ishizawa KI; Taniwaki M; Fujisawa S; Morishima Y; Tobinai K; Okada M; Ando K; Usui N; Miyawaki S; Utsunomiya A; Uoshima N; Nagai T; Naoe T; Motoji T; Jinnai I; Tanimoto M; Miyazaki Y; Ohnishi K; Iida S; Okamoto S; Seriu T; Ohno R
    Int J Hematol; 2009 Apr; 89(3):332-341. PubMed ID: 19263190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.
    Keskin D; Sadri S; Eskazan AE
    Drug Des Devel Ther; 2016; 10():3355-3361. PubMed ID: 27784993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
    Druker BJ
    Oncogene; 2002 Dec; 21(56):8541-6. PubMed ID: 12476300
    [No Abstract]   [Full Text] [Related]  

  • 36. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance.
    Travis J
    Science; 2004 Jul; 305(5682):319-21. PubMed ID: 15256643
    [No Abstract]   [Full Text] [Related]  

  • 38. [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
    Cony-Makhoul P; Bergeron A; Corm S; Dubruille V; Rea D; Rigal-Huguet F; Nicolini FE
    Bull Cancer; 2008 Sep; 95(9):805-11. PubMed ID: 18829412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.
    Hayette S; Chabane K; Michallet M; Michallat E; Cony-Makhoul P; Salesse S; Maguer-Satta V; Magaud JP; Nicolini FE
    Leuk Res; 2011 Jan; 35(1):38-43. PubMed ID: 20673586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dasatinib: an anti-tumour agent via Src inhibition.
    Gnoni A; Marech I; Silvestris N; Vacca A; Lorusso V
    Curr Drug Targets; 2011 Apr; 12(4):563-78. PubMed ID: 21226671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.